Riskpilot← Back to searchSign inGet full accessURO SØR NYGÅRD AS
ASActiveOrg 921318022Haraldsgata 164, 5525 HaugesundMedical specialists activities · NACE 8622Est. 20186 employees
Revenue 2024
NOK 11,9M
+5% vs 2023
EBITDA margin
16.0%
-33% vs 2023
Equity ratio
16.5%
Financial strength
Net profit 2024
NOK 1,1M
-31% vs 2023
| Revenue | NOK 11,9M | +5% |
| EBITDA | NOK 1,9M | -33% |
| Net profit | NOK 1,1M | -31% |
| Total assets | NOK 3,3M | -27% |
| Equity | NOK 541K | -5% |
| Employees | 6 | — |
Legal name
URO SØR NYGÅRD AS
Org number
921318022
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
30. august 2018
Share capital
NOK 30 000
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene eller styrets leder alene.
Company purpose
Spesialisert legevirksomhet innen urologi samt annen legevirksomhet som naturlig knytter seg til dette. Legetjenester.
Address
Haraldsgata 164, 5525 Haugesund
Phone
+4752731004
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 9 518 | 9 968 | 10 660 | 11 267 | 11 860 |
| Staff expenses | −4 015 | −4 345 | −5 224 | −5 237 | −5 291 |
| EBITDA | 3 147 | 3 454 | 2 812 | 2 849 | 1 903 |
| Depreciation & amort. | −783 | −856 | −962 | −782 | −473 |
| EBIT | 2 364 | 2 598 | 1 850 | 2 067 | 1 430 |
| Net financials | −30 | −18 | −39 | −27 | −17 |
| Profit before tax | 2 334 | 2 580 | 1 811 | 2 040 | 1 413 |
| Tax | 515 | 570 | 404 | 449 | 314 |
| Net profit | 1 819 | 2 009 | 1 407 | 1 591 | 1 099 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 883 | 5 683 | 5 325 | 4 523 | 3 286 |
| Equity | 879 | 1 016 | 782 | 571 | 541 |
| Long-term debt | 665 | 393 | 917 | 656 | 379 |
| Short-term debt | 4 340 | 4 274 | 3 626 | 3 296 | 2 366 |
| Total debt | 5 005 | 4 667 | 4 543 | 3 952 | 2 745 |
EBITDA margin
16.0%
This company
15.8%
Market median
+1% vs market
20202024
Equity ratio
16.5%
This company
38.2%
Market median
-57% vs market
20202024
Return on equity
203.1%
This company
18.4%
Market median
+1004% vs market
20202024
Net profit margin
9.3%
This company
8.1%
Market median
+15% vs market
20202024
Asset turnover
3.61×
This company
1.12×
Market median
+222% vs market
20202024
Debt / equity
5.07×
This company
0.62×
Market median
-718% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
YN Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2018 | |
| Former (1) | ||
| Chairman | 2018 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nygård & Nygård Consulting As
URO SØR NYGÅRD AS Board members of URO SØR NYGÅRD AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yngve Nygård | Chief Executive Officer | 0 companies |
| Ida Elisabeth Rosenlund Nygård | Chairman | 0 companies |
| Ida Elisabeth Nygård | Chairman | 0 companies |